Hormonal
Current use of hormone replacement therapy (HRT) with medium potency oestrogens significantly reduces the risk of hip fracture in postmenopausal women, with risk decreasing by 6% per year of use.
If you are a postmenopausal woman concerned about hip fractures, current use of hormone replacement therapy (HRT) with medium potency oestrogens can significantly reduce your risk. The protection increases with the duration of use, decreasing by about 6% for each year you take it. However, if you stop taking HRT for more than five years, most of this protection is lost. Low doses of oestrogen alone may not be effective, so discuss the appropriate dose and regimen with your healthcare provider.
Compared with women who had never used hormone replacement therapy, current users had an odds ratio of 0.35 (95 % confidence interval 0.24 to 0.53) for hip fracture... For every year of therapy, the overall risk decreased by 6% (3% to 9%)
Why this rating
Large population-based case-control study (n=1327 cases, n=3262 controls) with high response rates and rigorous adjustment for confounders.
Source
Hormone replacement therapy and risk of hip fracture: population based case-control study
Karl Michaëlsson et al. · BMJ · 1998
DOI 10.1136/bmj.316.7148.1858
More from this paper
- The protective effect of HRT on hip fracture risk diminishes significantly if treatment is stopped for more than five years, regardless of prior duration of use.Good
- Adding progestins to oestrogen therapy enhances the protective effect against hip fractures compared to oestrogen alone, allowing for lower oestrogen doses.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →